| Outcome Measures: |
Primary: Change From Baseline in Visual Analogue Scale for Pain, The Visual Analogue Scale for Pain varies from 0 to 10 cm. Higher values represent worse outcomes., Baseline, 4 weeks | Secondary: Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Pain, KOOS Pain consists of 9 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems., Baseline, 4 weeks|Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Activities of daily living (ADL), KOOS ADL consists of 17 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems., Baseline, 4 weeks|Knee injury and Osteoarthritis Outcome Score (KOOS) - subscale Symptoms, KOOS Symptoms consists of 7 items, which are answered on a 4-point likert scale (0=no problems, 4=extreme problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems., Baseline, 4 weeks|Quality of life with the The Short Form (36) Health Survey score, The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section.Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability., Baseline, 4 weeks|Intermittent and Constant Osteoarthritis Pain self-report questionnaire, Pain measure: Scale range 0-100 with higher scores indicating worse pain, Baseline, 4 weeks|Changes in serum levels of aggrecan, serum levels of aggrecan measured in ng/ml, Baseline, 4 weeks|Changes in serum levels of antibodies to collagen type II, serum levels of antibodies to collagen type II measured AU/ml, Baseline, 4 weeks|Changes in serum levels of C-reactive protein, serum levels of C-reactive protein (CRP), g/l, Baseline, 4 weeks|Changes in histamine levels, serum levels of histamine in ng/ml, Baseline, 4 weeks|Changes in inflammation biomarkers, serum levels of (CRP), interleukin (IL)-6, IL- 18, adiponectin, IL-10, and interferon (IFN) γ in pg/ml, Baseline, 4 weeks|Changes in neopterin levels, serum neopterin measured in nmol/L, Baseline, 4 weeks|Changes in lipid biomarkers, serum total cholesterol, HDL, and LDL measured in mmol/L, Baseline, 4 weeks|changes in diabetes control, Glycated haemoglobin (HbA1c), Baseline, 4 weeks|Changes in depression scores measured with Patient Health Questionnaire-9 (PHQ9P), The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. It consists of nine questions with responses ranging from "0" (not at all) to "3" (nearly every day). The possible range is 0-27. Higher values represent worse outcome., Baseline, 4 weeks|Patient global assessment of osteoarthritis, The Visual Analogue Scale for the Patient global assessment of osteoarthritis varies from 0 to 10 cm. Higher values represent worse outcomes., Baseline, 4 weeks
|
